INSIGHTS ON CELL & GENE CLINICAL TRIALS

• Parkinson's Disease: Asia Pacific Clinical Trial Landscape

  In the coming years, the global burden of Parkinson's Disease (PD) is expected to rise. The number of people with PD in Asia is anticipated to exceed 6 million by 2030. Discover the factors leading to this in this report.

• COVID-19: Asia Pacific Clinical Trial Landscape

  In December 2019, a novel coronavirus was discovered in China causing severe acute respiratory syndrome-like pneumonia which resulted in a pandemic. Find out more details regarding its spread in this report.

• Solid Tumors: Asia Pacific Clinical Trial Landscape

  A solid tumour arises from an abnormally growing mass of cancer cells in organ systems. Read about how one of the major world regions whose incidence and mortality rates are expected to rise dramatically is Asia.

• Gene Therapies: From Research To Reality

  Partnership scrutiny is critical for cell and gene sponsors transitioning from pure R&D and early preclinical work into clinical-phase development.

• Effective Medical Communications During CGT Clinical Trials

  Medical communications help crystalize the nuances of cell and gene therapies for patients and healthcare providers. For a successful cell or gene therapy launch, you'll need to draw attention to stakeholders early in clinical trials to effectively inform them of the value of the therapy in development. This article shares key tips for an effective strategy.

• Oncology Platforms And The Promise Of A Cure

  We discuss how a deepened understanding of cancer hallmarks and advances in science and engineering have set the stage for emerging therapeutic platforms.

• 5 Patient Engagement & Recruitment Trends, And How To Keep Up With Them

  From decentralized trials to real world data, take a look at top trends, their impact on patient enrollment and more, as well as ways to stay ahead of the curve.

• The Role Of Real World Evidence To Support US FDA And TGA Registrations

  Real world evidence (RWE) can contribute valuable information to new medicine registrations, in particular for diseases that are difficult to assess in randomized clinical trials (RCTs) and for emerging technologies.

• Next Generation Sequencing In The Asia Pacific: The Availability & Reimbursement Landscape

  Next generation sequencing (NGS) refers to a technology that detects genomic variation that is present at birth or emerges later in life. This report describes the availability of NGS in a selection of locations.

• Modern Technologies Transforming Clinical Development In The APAC Region

  In this white paper, gain insight into how the Asia Pacific region, with its rapid growth of clinical trials, presents a great opportunity for conducting clinical research and has become the preferred destination for DCTs.